Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks News

ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?

ResMed (RMD) gains from impressive performance of its SaaS business.

Here's Why You Should Add Omnicell to Your Portfolio Now

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

Omnicell (OMCL) partners Huron to provide customers with committed expertise.

Worried About Market Downturn? Buy These Low Leverage Stocks

Debt is a much cheaper form of financing than equity. Yet the fact that debt carries the burden of interest payments makes it dearer.

Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

Omnicell to Feature Upgrades in Medication Management at ASHP

Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.

Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education

Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

Aparajita Dutta headshot

Buy These 5 Low Leverage Stocks to Keep Your Portfolio Safe

To safeguard one's portfolio from massive losses, the real challenge for an investor is to determine whether an organization's debt level is sustainable.

SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?

SYNH vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

Omnicell (OMCL) Q3 Earnings Surpass Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell Advances on Global Footing Despite Severe Rivalry

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Sreyoshi Mukherjee headshot

Bright Near-Term Outlook for Medical Info Systems Industry

Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.

Omnicell's Autonomous Pharmacy to Boost Medication Management

Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.

Omnicell (OMCL) Up 0.4% Since Last Earnings Report: Can It Continue?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

Investor confidence continues to be high on Omnicell's (OMCL) prospects.

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell (OMCL) aims at product innovation through R&D.

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 4.69% and 1.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.